Landscape Capital Management L.L.C. Has $2.17 Million Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Landscape Capital Management L.L.C. boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 292.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 178,766 shares of the company's stock after acquiring an additional 133,232 shares during the quarter. Landscape Capital Management L.L.C.'s holdings in Elanco Animal Health were worth $2,165,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ELAN. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health in the 3rd quarter valued at about $35,000. Jones Financial Companies Lllp lifted its position in shares of Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after buying an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. boosted its stake in shares of Elanco Animal Health by 221.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after acquiring an additional 3,411 shares during the period. MRP Capital Investments LLC acquired a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $61,000. Finally, Blue Trust Inc. raised its stake in Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after acquiring an additional 1,894 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Insiders Place Their Bets

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction dated Tuesday, March 11th. The shares were bought at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the purchase, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.57% of the company's stock.

Elanco Animal Health Price Performance

Elanco Animal Health stock traded down $0.99 during mid-day trading on Thursday, reaching $8.39. 2,865,860 shares of the company were exchanged, compared to its average volume of 4,871,163. The firm has a market cap of $4.16 billion, a PE ratio of 21.09, a PEG ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a fifty day simple moving average of $10.71 and a 200-day simple moving average of $12.10. Elanco Animal Health Incorporated has a 12 month low of $8.03 and a 12 month high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm's revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.08 EPS. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ELAN. UBS Group reduced their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Piper Sandler decreased their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Barclays cut their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Morgan Stanley decreased their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus dropped their price target on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a report on Friday, February 21st. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.